BCAX — BICARA THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About BICARA THERAPEUTICS INC (BCAX)
BICARA THERAPEUTICS INC (BCAX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $34M. Across recent filings, tracked investors recorded 4 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in BCAX
How many top investors track BCAX
A small number of top investors own this.
BCAX Ownership Composition
How BICARA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other100.0%
Tracked investors reporting BCAX
- Ken GriffinMar 31, 2026Citadel AdvisorsShares1.7MValue$34.3M% Portfolio0.01%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares156.7KValue$3.1M% Portfolio0.00%
- Paul Tudor JonesDec 31, 2025Tudor Investment CorpShares27.4KValue$461K% Portfolio0.00%
Recent activity
- $461KFeb 17, 2026
- $7.3MFeb 17, 2026
- $3.1MMay 15, 2026
- New$34.3MMay 15, 2026
Frequently asked questions
- How many institutional investors hold BCAX?
- 3 tracked institutional investors disclosed a position in BCAX (BICARA THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of BCAX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in BCAX, valued at $34M.
- Did institutional ownership of BCAX increase or decrease?
- Across recent 13F filings, tracked investors recorded 4 new positions, 0 increased, 0 reduced, and 0 fully exited BCAX.
- Where does this BCAX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.